Welcome to our dedicated page for PALVELLA THERAPEUTICS SEC filings (Ticker: PVLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Palvella Therapeutics, Inc. (Nasdaq: PVLA) SEC filings page on Stock Titan provides access to the company’s official disclosures as a clinical-stage biopharmaceutical issuer. Palvella’s filings describe a business focused on developing investigational topical therapies for serious, rare skin diseases and vascular malformations with no FDA-approved therapies, built around its patented QTORIN™ platform.
Through documents such as Form 8-K current reports, investors can review how Palvella communicates material events, including topline results from the Phase 2 TOIVA trial of QTORIN™ rapamycin for cutaneous venous malformations, updates on the Phase 3 SELVA trial in microcystic lymphatic malformations, and announcements of new product candidates like QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis. Other 8-K filings furnish earnings press releases, corporate presentations, and information about conference calls related to quarterly financial results and corporate updates.
These filings also confirm key structural details, such as Palvella’s incorporation in Nevada, its listing of common stock on The Nasdaq Capital Market under the symbol PVLA, and its description as a clinical-stage company. Regulation FD disclosures provide slide decks and presentations that elaborate on the company’s pipeline, regulatory designations, and development plans, while results-of-operations filings supply context on research and development spending and general and administrative costs associated with advancing QTORIN™ programs.
On Stock Titan, users can combine real-time updates from EDGAR with AI-assisted views of Palvella’s filings to more quickly understand the significance of new 8-Ks and related exhibits. This includes identifying which filings discuss clinical data, regulatory interactions, or financial performance, and how those disclosures relate to the company’s investigational product candidates, all while recognizing that QTORIN™ rapamycin and QTORIN™ pitavastatin remain unapproved therapies.
PALVELLA THERAPEUTICS, INC. (PVLA) director Christopher P. Kiritsy reported an option exercise and related share sale. On September 2, 2026, he exercised a fully vested stock option for 313 shares of common stock at an exercise price of $127.20 per share, a figure adjusted for the company’s 1-for-80 reverse stock split that became effective on April 23, 2024. He then sold 313 shares of common stock at $157.00 per share on the same date, and the exercised option position is reported as fully exhausted in this filing.
PALVELLA THERAPEUTICS, INC. (PVLA) is the issuer for a proposed sale of common stock reported under Rule 144 by stockholder Christopher Kiritsy. The notice covers 375 shares of common stock, with an indicated value of $58,875.00, to be sold through Morgan Stanley Smith Barney LLC on or after September 2, 2026.
The shares are to be issued in connection with a stock option exercise, with the issuer listed as the party for the option exercise and cash as the form of payment. The securities are listed as trading on NASDAQ.
PALVELLA THERAPEUTICS, INC. (PVLA) reported that Chief Operating Officer Kathleen Goin exercised stock options covering 4,302 shares of common stock on August 19, 2026, at exercise prices of $7.14 and $9.08 per share, and sold 4,302 shares in multiple open-market transactions at prices between $150.62 and $156.77 per share. These trades were executed under a Rule 10b5-1 trading plan adopted on August 19, 2025, and the exercised options were fully vested.
PALVELLA THERAPEUTICS, INC. (symbol PVLA) received a Rule 144 notice indicating that officer Kathleen Goin, through broker Piper Sandler & Co., intends to sell 4,302 shares of common stock, with an aggregate market value of $647,106.84, around 08/19/2026 on Nasdaq. Shares outstanding are reported as 14,408,407. Over the prior three months, Goin reported three separate sales of 4,302 shares each, with aggregate prices of $475,630.84, $476,372.94, and $642,191.37.
First Light Asset Management, LLC and Mathew P. Arens report beneficial ownership of 769,117 shares of Palvella Therapeutics, Inc. common stock, representing 5.34% of the class. The shares are held in separately managed accounts and private funds for which First Light serves as investment adviser.
Both reporting persons have shared voting and dispositive power over the 769,117 shares and no sole voting or dispositive power. They state that beneficial ownership is reported solely for Section 13(d) purposes and is not an admission of beneficial ownership for other purposes.
Palvella Therapeutics, Inc. is the subject of an amended Schedule 13G reporting updated passive ownership by a group of Biotechnology Value Fund entities and Mark N. Lampert. As of the close of business on June 30, 2026, the group, through various Delaware and Cayman Islands funds and managers, beneficially owned 672,789 shares of Palvella common stock in the aggregate. Based on 14,342,844 shares outstanding as of May 1, 2026, this represents approximately 4.7% of the company’s common stock, with each individual fund holding between less than 1% and 2.5%. The filing notes that several entities and Mr. Lampert may be deemed to share voting and dispositive power over these shares and that multiple parties expressly disclaim beneficial ownership of shares held by affiliated entities. The group reports ownership of 5 percent or less of the class.
Prudential Financial, Inc. reported beneficial ownership of common stock of Palvella Therapeutics, Inc. as of June 30, 2026. Prudential and its subsidiaries beneficially owned 962,374 shares of Palvella common stock, representing 6.7% of the class. Prudential reported 0 shares with sole voting or dispositive power, and 826,531 shares with shared voting power and 962,374 shares with shared dispositive power. The stake is held through subsidiaries including Jennison IA with 960,619 shares (6.7%) and PGIM Quantitative Solutions LLC with 1,755 shares. Prudential noted that its clients may have rights to receive dividends or sale proceeds related to these securities.
Palvella Therapeutics is a late clinical-stage biopharmaceutical company focused on serious, rare skin diseases and vascular malformations. For the six months ended June 30, 2026, it advanced lead topical candidate QTORIN rapamycin toward U.S. approval for microcystic lymphatic malformations, with a rolling NDA underway and the first module submitted; completion is targeted for the second half of 2026. QTORIN is also in Phase 2 development for cutaneous venous malformations and clinically significant angiokeratomas, and IND-enabling work continues for QTORIN pitavastatin in disseminated superficial actinic porokeratosis.
Palvella reported a net loss of $37.6 million for the six-month period, compared with $17.7 million a year earlier, reflecting higher research and development and general and administrative spending, including stock-based compensation. An underwritten equity offering generated $215.8 million in net proceeds, lifting cash and short-term investments to $250.6 million at June 30, 2026. Management expects this liquidity to fund operations for at least 12 months while the company continues clinical programs and services a Ligand funding and royalty agreement liability linked to future QTORIN sales.
Palvella Therapeutics reported Q2 2026 results while advancing its rare‑disease dermatology pipeline. Cash, cash equivalents and short‑term investments were $250.6 million as of June 30, 2026, supported by an upsized $230 million equity raise in February and projected 2026 cash use of $85–$95 million.
Research and development expense was $12.5 million and general and administrative expense was $8.9 million for the quarter, resulting in a net loss of $21.9 million, or $1.52 per share. Spending increased mainly for manufacturing, QTORIN rapamycin NDA preparation, angiokeratomas development, and public‑company infrastructure.
Palvella completed a pre‑NDA meeting and submitted the first module of a rolling NDA to the FDA for QTORIN rapamycin in microcystic lymphatic malformations, targeting completion of the filing in the second half of 2026 and a potential standalone U.S. launch in the first half of 2027, if approved. Additional Phase 2 and Phase 3 studies across cutaneous venous malformations, clinically significant angiokeratomas, and DSAP are planned or underway.
Jennison Associates LLC reports a significant ownership stake in Palvella Therapeutics Inc. common stock. As of June 30, 2026, Jennison beneficially owned 960,619 shares, representing 6.7% of the class.
Jennison has sole power to vote these 960,619 shares and shared power to dispose of 960,619 shares, with no shared voting power and no sole dispositive power reported.